Novartis (NVS)
(Delayed Data from NYSE)
$106.13 USD
-1.09 (-1.02%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $106.13 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NVS 106.13 -1.09(-1.02%)
Will NVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVS
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Other News for NVS
Why Novartis Deserves Your Attention After Q2 2024 Results
Novartis AG (NOVN) Receives a Hold from J.P. Morgan
Novartis just downgraded at Deutsche Bank, here's why
Deutsche Numis downgrades Novartis AG (NOVN) to a Hold
Barclays Keeps Their Sell Rating on Novartis AG (NOVN)